WO2009103790A3 - Procédé et trousse de détection des gènes associés à la mutation du pik3ca et impliqués dans l’activation de la voie pi3k/akt dans les sous-types er-positifs et her2-positifs avec des implications cliniques. - Google Patents
Procédé et trousse de détection des gènes associés à la mutation du pik3ca et impliqués dans l’activation de la voie pi3k/akt dans les sous-types er-positifs et her2-positifs avec des implications cliniques. Download PDFInfo
- Publication number
- WO2009103790A3 WO2009103790A3 PCT/EP2009/052043 EP2009052043W WO2009103790A3 WO 2009103790 A3 WO2009103790 A3 WO 2009103790A3 EP 2009052043 W EP2009052043 W EP 2009052043W WO 2009103790 A3 WO2009103790 A3 WO 2009103790A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- positive
- pi3k
- her2
- kit
- involved
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Abstract
L’invention concerne un procédé pour déterminer le résultat clinique d’une tumeur du sein qui touche une patiente si elle est traitée avec un agent antitumoral contre la tumeur du sein, ledit procédé comprenant l’étape d’analyse d’un échantillon d’une tumeur du sein provenant de ladite patiente pour un taux d’expression des gènes sélectionnés, en mettant les séquences d’ARNm provenant des cellules de cette tumeur du sein en contact avec un ensemble de plus de trois séquences de nucléotides liées au PIK3CA humain muté.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09712209A EP2247756A2 (fr) | 2008-02-21 | 2009-02-20 | Procédé et trousse de détection des gènes associés à la mutation du pik3ca et impliqués dans l activation de la voie pi3k/akt dans les sous-types er-positifs et her2-positifs avec des implications cliniques. |
US12/860,638 US8580496B2 (en) | 2008-02-21 | 2010-08-20 | Method and kit for the detection of genes associated with PIK3CA mutation and involved in PI3K/AKT pathway activation in the ER-postitive and HER2-positive subtypes with clinical implications |
US14/032,984 US20140056881A1 (en) | 2008-02-21 | 2013-09-20 | Method and kit for the detection of genes associated with pik3ca mutation and involved in pi3k/akt pathway activation in the er-postitive and her2-positive subtypes with clinical implications |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3045008P | 2008-02-21 | 2008-02-21 | |
US61/030,450 | 2008-02-21 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/860,638 Continuation-In-Part US8580496B2 (en) | 2008-02-21 | 2010-08-20 | Method and kit for the detection of genes associated with PIK3CA mutation and involved in PI3K/AKT pathway activation in the ER-postitive and HER2-positive subtypes with clinical implications |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009103790A2 WO2009103790A2 (fr) | 2009-08-27 |
WO2009103790A3 true WO2009103790A3 (fr) | 2009-11-12 |
Family
ID=40751088
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2009/052043 WO2009103790A2 (fr) | 2008-02-21 | 2009-02-20 | Procédé et trousse de détection des gènes associés à la mutation du pik3ca et impliqués dans l’activation de la voie pi3k/akt dans les sous-types er-positifs et her2-positifs avec des implications cliniques. |
Country Status (3)
Country | Link |
---|---|
US (2) | US8580496B2 (fr) |
EP (1) | EP2247756A2 (fr) |
WO (1) | WO2009103790A2 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7897356B2 (en) | 2008-11-12 | 2011-03-01 | Caris Life Sciences | Methods and systems of using exosomes for determining phenotypes |
US8700335B2 (en) | 2006-05-18 | 2014-04-15 | Caris Mpi, Inc. | System and method for determining individualized medical intervention for a disease state |
US8768629B2 (en) | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103237901B (zh) | 2010-03-01 | 2016-08-03 | 卡里斯生命科学瑞士控股有限责任公司 | 用于治疗诊断的生物标志物 |
WO2011127219A1 (fr) | 2010-04-06 | 2011-10-13 | Caris Life Sciences Luxembourg Holdings | Biomarqueurs circulants pour une maladie |
US20130295571A1 (en) * | 2010-10-29 | 2013-11-07 | Institut National De La Santee Et De La Recherche Medicale ( Inserm) | Marker of breast tumors from the luminal-b subtype |
EP2663652B1 (fr) * | 2011-01-11 | 2018-11-14 | Roche Diagniostics GmbH | Analyse haute résolution des courbes de fusion à titre d'outil de précriblage |
WO2012130720A2 (fr) * | 2011-03-28 | 2012-10-04 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Prédiction de la sensibilité vis-à-vis d'inhibiteurs de pi3k/mtor |
KR102165122B1 (ko) * | 2011-04-01 | 2020-10-13 | 제넨테크, 인크. | 암 치료에 대한 감수성을 예측하기 위한 바이오마커 |
FR2976294B1 (fr) * | 2011-06-10 | 2018-02-16 | Universite De Nice Sophia Antipolis | Methode de prediction de la reponse a un traitement avec un agent bloquant her2 |
GB201114051D0 (en) * | 2011-08-15 | 2011-09-28 | Domainex Ltd | Compounds and their uses |
MX2014014831A (es) | 2012-06-08 | 2015-02-12 | Hoffmann La Roche | Selectividad de mutante y combinaciones de un compuesto inhibidor de fosfoinositida 3 cinasa y agentes quimioterapeuticos para el tratamiento de cancer. |
RU2015140573A (ru) | 2013-02-25 | 2017-03-30 | Дженентек, Инк. | Способы и композиции для обнаружения и лечения устойчивого к лекарственным средствам мутанта акт |
WO2015164238A1 (fr) * | 2014-04-21 | 2015-10-29 | Mayo Foundation For Medical Education And Research | Matériels et méthodes pour identifier et traiter des mammifères ayant un cancer du sein her2-positif |
CN112941187A (zh) * | 2021-04-02 | 2021-06-11 | 无锡市第五人民医院 | 一种乳腺癌相关基因pik3ca-q928h突变体及其特异性引物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050186577A1 (en) * | 2004-02-20 | 2005-08-25 | Yixin Wang | Breast cancer prognostics |
US20070172844A1 (en) * | 2005-09-28 | 2007-07-26 | University Of South Florida | Individualized cancer treatments |
WO2007109026A2 (fr) * | 2006-03-15 | 2007-09-27 | The Trustees Of Columbia University In The City Of New York | Compositions de pten et méthodes servant à détecter le cancer du sein |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1980629A3 (fr) | 2003-08-28 | 2008-12-17 | Ipsogen | Identification d'une signature d'expression de gène erbb2 dans les cancers du sein |
EP1704416A2 (fr) | 2004-01-16 | 2006-09-27 | Ipsogen | Etablissement de profils d'expression de proteines et prognose du cancer du sein |
CN101356532B (zh) | 2005-05-13 | 2012-08-01 | 布鲁塞尔自由大学 | 基于基因的算法型癌症预后 |
-
2009
- 2009-02-20 EP EP09712209A patent/EP2247756A2/fr not_active Withdrawn
- 2009-02-20 WO PCT/EP2009/052043 patent/WO2009103790A2/fr active Application Filing
-
2010
- 2010-08-20 US US12/860,638 patent/US8580496B2/en not_active Expired - Fee Related
-
2013
- 2013-09-20 US US14/032,984 patent/US20140056881A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050186577A1 (en) * | 2004-02-20 | 2005-08-25 | Yixin Wang | Breast cancer prognostics |
US20070172844A1 (en) * | 2005-09-28 | 2007-07-26 | University Of South Florida | Individualized cancer treatments |
WO2007109026A2 (fr) * | 2006-03-15 | 2007-09-27 | The Trustees Of Columbia University In The City Of New York | Compositions de pten et méthodes servant à détecter le cancer du sein |
Non-Patent Citations (9)
Title |
---|
CLARK A S ET AL: "CONSTITUTIVE AND INDUCIBLE AKT ACTIVITY PROMOTES RESISTANCE TO CHEMOTHERAPY, TRASTUZUMAB, OR TAMOXIFEN IN BREAST CANCER CELLS", MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION OF CANCER RESEARCH, US, vol. 1, no. 9, 1 July 2002 (2002-07-01), pages 707 - 717, XP009056214, ISSN: 1535-7163 * |
DAVID J VILLENEUVE ET AL: "cDNA microarray analysis of isogenic paclitaxel and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance", BREAST CANCER RESEARCH AND TREATMENT, KLUWER ACADEMIC PUBLISHERS, BO, vol. 96, no. 1, 1 March 2006 (2006-03-01), pages 17 - 39, XP019274976, ISSN: 1573-7217 * |
ISAKOFF STEVEN J ET AL: "Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells", CANCER RESEARCH, vol. 65, no. 23, December 2005 (2005-12-01), pages 10992 - 11000, XP002534440, ISSN: 0008-5472 * |
OH DANIEL S ET AL: "Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 10 APR 2006, vol. 24, no. 11, 10 April 2006 (2006-04-10), pages 1656 - 1664, XP002534381, ISSN: 1527-7755 * |
RODRIGUEZ A A ET AL: "BRCA1 gene expression signature predicts for anthracycline-chemosensitivity in triple-negative breast cancer.", CANCER RESEARCH, vol. 69, no. 2, Suppl. S, January 2009 (2009-01-01), & 31ST ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM; SAN ANTONIO, TX, USA; DECEMBER 10 -14, 2008, pages 358S, XP002534183, ISSN: 0008-5472 * |
See also references of EP2247756A2 * |
STEMKE-HALE KATHERINE ET AL: "An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.", CANCER RESEARCH 1 AUG 2008, vol. 68, no. 15, 1 August 2008 (2008-08-01), pages 6084 - 6091, XP002534389, ISSN: 1538-7445 * |
TOKUNAGA E ET AL: "The association between Akt activation and resistance to hormone therapy in metastatic breast cancer", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 42, no. 5, 1 March 2006 (2006-03-01), pages 629 - 635, XP025104813, ISSN: 0959-8049, [retrieved on 20060301] * |
WOO CHUL NOH ET AL: "Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables", BREAST CANCER RESEARCH AND TREATMENT, KLUWER ACADEMIC PUBLISHERS, BO, vol. 110, no. 3, 6 September 2007 (2007-09-06), pages 477 - 483, XP019600711, ISSN: 1573-7217 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8700335B2 (en) | 2006-05-18 | 2014-04-15 | Caris Mpi, Inc. | System and method for determining individualized medical intervention for a disease state |
US7897356B2 (en) | 2008-11-12 | 2011-03-01 | Caris Life Sciences | Methods and systems of using exosomes for determining phenotypes |
US8768629B2 (en) | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
Also Published As
Publication number | Publication date |
---|---|
EP2247756A2 (fr) | 2010-11-10 |
US8580496B2 (en) | 2013-11-12 |
US20140056881A1 (en) | 2014-02-27 |
US20110038862A1 (en) | 2011-02-17 |
WO2009103790A2 (fr) | 2009-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009103790A3 (fr) | Procédé et trousse de détection des gènes associés à la mutation du pik3ca et impliqués dans l’activation de la voie pi3k/akt dans les sous-types er-positifs et her2-positifs avec des implications cliniques. | |
Pignot et al. | microRNA expression profile in a large series of bladder tumors: identification of a 3‐miRNA signature associated with aggressiveness of muscle‐invasive bladder cancer | |
Ratert et al. | miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome | |
Li et al. | Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance | |
Hoppe et al. | Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment | |
Spahn et al. | Expression of microRNA‐221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence | |
Schaefer et al. | Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma | |
Flavin et al. | Potentially important microRNA cluster on chromosome 17p13. 1 in primary peritoneal carcinoma | |
Wang et al. | Clinicopathologic significance of miR-10b expression in gastric carcinoma | |
WO2007114896A3 (fr) | Procédé de pronostic et de diagnostic destiné à une cancérothérapie | |
Zhang et al. | MicroRNA‐1322 regulates ECRG2 allele specifically and acts as a potential biomarker in patients with esophageal squamous cell carcinoma | |
WO2008076447A3 (fr) | Traitements de maladies résistantes aux thérapies et combinaisons médicamenteuses pour traiter celles-ci | |
Sha et al. | Association study of the let-7 miRNA-complementary site variant in the 3′ untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial) | |
Sun et al. | A nine-lncRNA signature predicts distant relapse-free survival of HER2-negative breast cancer patients receiving taxane and anthracycline-based neoadjuvant chemotherapy | |
NZ593229A (en) | Gene expression markers (gadd45b) for colorectal cancer prognosis | |
WO2011109584A3 (fr) | Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de kinase du récepteur du facteur de croissance insulinique 1 | |
EP2610347A3 (fr) | Procédés de détermination du pronostic d'un sujet avec un cancer du pancréas | |
JP2012500389A5 (fr) | ||
WO2007085497A3 (fr) | Marqueurs de prévision des résultats d'un traitement à l'anthracycline | |
NZ627864A (en) | Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status | |
WO2005118875A3 (fr) | Diagnostic et prévision de l’évolution du cancer du sein | |
WO2010051314A3 (fr) | Classification génomique de carcinomes pulmonaires non à petites cellules en fonction de profils d'altérations du nombre de copies de gènes | |
He et al. | Expression of circulating microRNA-20a and let-7a in esophageal squamous cell carcinoma | |
WO2002070750A3 (fr) | Methodes permettant de determiner l'expression genique de la dihydropyrimidine deshydrogenase | |
Xu et al. | A genetic polymorphism in pre-miR-27a confers clinical outcome of non-small cell lung cancer in a Chinese population |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09712209 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009712209 Country of ref document: EP |